Cargando…

Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report

The first-line treatment for metastatic esophageal squamous cell cancer (ESCC) is a platinum- or fluorouracil-based agent, followed by later treatment with taxanes or irinotecan. However, there is still no standard third-line treatment for patients with metastatic ESCC. We present a 62-year-old man...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Li-Jun, Wen, Yi-Xuan, Xia, You-You, Wang, Lei, Fei, Jia-Yan, Jiang, Xiao-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145360/ https://www.ncbi.nlm.nih.gov/pubmed/30271164 http://dx.doi.org/10.2147/OTT.S174429

Ejemplares similares

Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer
por: Li, Jing, et al.
Publicado: (2019)

Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
por: Zhao, Jian, et al.
Publicado: (2019)

Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer
por: Liang, Li-jun, et al.
Publicado: (2020)

Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
por: Jia, Jun, et al.
Publicado: (2021)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
por: Zhang, Hong-Hong, et al.
Publicado: (2022)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17
por: Chen, Ran, et al.
Publicado: (2019)

Efficacy and safety of apatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma: a retrospective multi-center study
por: Liu, Zijing, et al.
Publicado: (2022)

Apatinib for salvage treatment of advanced malignant pleural mesothelioma: A case report
por: Du, Zedong, et al.
Publicado: (2018)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
por: Shi, Liang, et al.
Publicado: (2022)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel
por: Yun, Tianyang, et al.
Publicado: (2015)

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
por: Yang, Zhi-Ran, et al.
Publicado: (2022)

Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study
por: Zhao, Feng, et al.
Publicado: (2017)

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy
por: Chi, Dongmei, et al.
Publicado: (2021)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial
por: Song, Yong, et al.
Publicado: (2020)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
por: Yagi, Koichi, et al.
Publicado: (2021)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
por: Yang, Bo, et al.
Publicado: (2022)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review
por: Li, Cheng-Ming, et al.
Publicado: (2017)

Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways
por: Zhen, Hongchao, et al.
Publicado: (2020)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Patients with Metastatic Colorectal Cancer after Failure of Second-Line Treatment May Benefit from Low-Dose Apatinib and S-1 Combined with Jianpi Bushen Jiedu Decoction
por: Chen, Yue, et al.
Publicado: (2022)

Apatinib Combined with Irinotecan in the Treatment of Advanced Small-Cell Esophageal Carcinoma: A Case Report
por: Guo, Longhua, et al.
Publicado: (2021)

Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma
por: Yajima, Satoshi, et al.
Publicado: (2021)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer
por: Su, Meng, et al.
Publicado: (2019)

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
por: Qiu, Xian, et al.
Publicado: (2022)

Downregulation of fibulin‐4 inhibits autophagy and promotes the sensitivity of esophageal squamous cell carcinoma cells to apatinib by activating the Akt‐mTOR signaling pathway
por: Chen, Xiangyu, et al.
Publicado: (2022)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
por: Jiang, Qian, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib
por: Wang, Wei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_879f7t66nvr02qnapcfbsoesro